[ad_1]
Pfizer caused a global surprise by announcing that it would ask the United States Food and Drug Administration to authorize a third dose of his vaccine against the coronavirus. The application will be based on the results of studies which indicate that the efficacy against the new variants of the virus increased significantly with a third application.
It didn’t take long for voices to oppose what had been said since Pfizer. The United States Centers for Disease Control (CDC) was the first to speak. In a joint statement, they said that for now “there is no need for a third dose“.
For its part, Pfizer has shown data to support its claim: according to a relay carried out in Israel, the effectiveness of its vaccine against the Delta variant, it was 64 percent. They also pointed out that third dose between 5 and 10 times more antibodies are generated than with the second dose.
The reality is that an extra dose of vaccine may be more effective in preventing mild symptoms of the disease, there are no large variations in its effectiveness in stopping the risk of hospitalization and death from Covid. This means that, as the CDC noted, there is no compelling need to approve the third dose.
What will happen in the future with the third dose?
US health authorities have not completely ruled out the possibility of applying a dose greater than the vaccine of Pfizer. But they stressed that for a decision to be made in this direction, they will need to conduct a rigorous study that reliably determines the effectiveness against the delta variant, which is currently the one worrying the whole world.
Other organizations he claimed for the lack of “scientific basis” for the demand for Pfizer these were the WHO and the European Medicines Agency.
For now, the most effective way to combat the coronavirus in any of its variants is to apply the vaccines the way it was done. The figures in the United States show it: in the state of Maryland, for example, 93% of hospitalizations and 100% of new deaths from covid were in unvaccinated people.
.
[ad_2]
Source link